Can-Fite Biopharma Ltd is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer and other serious diseases
The company leverages its proprietary drug development platform to create targeted molecular medicines, which are designed to treat conditions such as psoriasis, liver disease, and various types of cancer. Can-Fite is dedicated to advancing its clinical trials and bringing promising therapies to market, with an emphasis on improving patient outcomes and addressing unmet medical needs in the pharmaceutical landscape.
Can-Fite BioPharma Ltd (NYSECANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months ended December 31, 2021.
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
Sign up for this week’s All Access giveaway here! Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSECANF), was a guest on Benzinga’s All Access on Nov 4, 2022.
Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study
Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over 7.5 million people.
